Patient Characteristics
| Characteristic | Data |
|---|---|
| Age (y) | |
| Mean | 48.1 (SD, 17.3) |
| Median | 54.0 (range, 18.0, 89.0) |
| Sex | |
| Female | 23 (48.9%) |
| Male | 24 (51.1%) |
| Sarcoma type | |
| Bone sarcoma | 20 (42.6%) |
| Osteosarcoma | 8 (17.0%) |
| Ewing sarcoma | 2 (4.3%) |
| Others | 10 (21.3%) |
| Soft-tissue sarcoma | 27 (57.4%) |
| Not otherwise specified/ undifferentiated pleomorphic sarcoma | 6 (12.8%) |
| Leiomyosarcoma | 4 (8.5%) |
| Others | 17 (36.2%) |
| Grading | |
| High grade | 35 (74.5%) |
| Low grade | 5 (10.6%) |
| Not applicable | 7 (14.9%) |
| Staging | |
| Localized | 16 (34.0%) |
| Synchrone metastasized | 9 (19.1%) |
| Metachrone metastasized | 22 (46.8%) |
| Prior therapies | |
| Chemotherapy | 13 (27.7%) |
| Chemotherapy and radiotherapy | 15 (31.9%) |
| Radiotherapy | 2 (4.3%) |
| None | 17 (36.2%) |
| Indication for PET | |
| Staging | 17 (36.2%) |
| Restaging | 20 (42.6%) |
| Localization before local therapy | 10 (21.3%) |
| Intended treatment before PET | |
| Chemotherapy | 26 (55.3%) |
| Resection | 12 (25.5%) |
| Radiation | 5 (10.6%) |
| Resection/radiation | 2 (4.3%) |
| Watch and wait | 2 (4.3%) |
Data are number followed by percentage in parentheses, except for age. Total n = 47.